Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-associated death
worldwide. Angiogenesis, the process of formation of new blood vessels, is required for …

Hepatocellular Carcinoma (HCC) continues to pose a substantial global health challenge
due to its high incidence and limited therapeutic options. In recent years, the Janus Kinase …

Carnitine metabolism is thought to be negatively correlated with the progression of
hepatocellular carcinoma (HCC) and the specific molecular mechanism is yet to be fully …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide.
Tyrosine kinase inhibitors (TKIs) remain the backbone of systematic therapy for advanced …

Primary liver cancer has become the second most fatal cancer in the world, and its five-year
survival rate is only 10%. Most patients are in the middle and advanced stages at the time of …

Being the sixth most diagnosed cancer and the fourth leading cause of cancer-related
deaths worldwide, liver cancer is considered as a serious disease with a high prevalence …

Cases of hepatocellular carcinoma (HCC) are rapidly rising. This is particularly the case in
the Western world, as a result of increasing rates of chronic liver disease, secondary to …

Abstract Treatment resistance is one of the major barriers for therapeutic strategies in
hepatocellular carcinoma (HCC). Many studies have indicated that chemotherapy and …

Globally, primary liver cancer is the third leading cause of cancer death, and hepatocellular
carcinoma (HCC) accounts for 75%–95%. The tumor microenvironment (TME), composed of …

The local microenvironment where tumors develop can shape cancer progression and
therapeutic outcome. Emerging evidence demonstrate that the efficacy of immune …